-
摘要:
胰腺癌是一种死亡率高、侵袭性强的恶性肿瘤，临床诊断和治疗目前没有较大进展。晚期确诊、早期侵袭转移和化放疗抵抗是预后差的关键因素。研究发现微小RNA的异常表达与胰腺癌有关。微小RNA是一类小非编码RNA分子，常通过降解靶基因mRNA或抑制其翻译，调控靶基因表达，从而参与肿瘤的发生发展。最新研究发现微小RNA在胰腺癌组织、血循环和其他体液中存在差异性表达，有助于胰腺癌诊断，而促癌或抑癌性微小RNA在肿瘤增殖、凋亡、进展中起重要作用，有望成为新的治疗靶点。因此，进一步深入研究胰腺癌诊断、治疗和预后相关的微小RNA，有利于从不同角度理解胰腺癌发病机制，为抗癌提供新思路。
Abstract:Pancreatic cancer is a malignant tumor with high mortality and strong invasion,meanwhile,lacking of significant breakthroughs in the diagnosis and treatment. The poor prognosis is attributed to many factors,of which the key ones are the late stage when patients are diagnosed,early invasion and metastasis,and resistance to chemotherapy and radiotherapy. Recently,more and more researches indicate that the abnormal expression of microRNA(miRNA) is associated with pancreatic cancer. miRNAs are a class of small non-coding RNAs involved in tumor initiation and development via degrading its mRNA or inhibiting its translation to regulate the expression of target gene. The latest studies suggest that the differential expression of miRNA in tumor tissues,blood circulation and other body fluids may contribute to the diagnosis of pancreatic cancer,and both of onco-miRNA and suppressor miRNA play an important role in the tumor proliferation,apoptosis and progression,being expected to be the new therapeutic targets of pancreatic cancer. Therefore,further researches on miRNAs related to diagnosis,treatment and prognosis of pancreatic cancer will give insight into its pathogenesis from a different side and open new avenues for anti-cancer strategies.
-
Key words:
- Pancreatic cancer /
- MicroRNA /
- Diagnosis /
- Treatment /
- Prognosis
-
-
[1] Kamisawa T,Wood LD,Itoi T,et al. Pancreatic cancer[J].Lancet,2016,pii: S0140-6736(16)00141-0. [Epub ahead of print]
[1] Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer[J].Lancet, 2016, pii: S0140-6736(16)00141-0. [Epub ahead of print] [2] Chan B, Manley J, Lee J, et al. The emerging roles of microRNAs in cancer metabolism[J]. Cancer Lett, 2015, 356(2 Pt A): 301-8. [2] Chan B,Manley J,Lee J,et al. The emerging roles of microRNAs in cancer metabolism[J]. Cancer Lett,2015,356(2 Pt A): 301-8. http://cn.bing.com/academic/profile?id=2071966633&encoded=0&v=paper_preview&mkt=zh-cn
[3] Rachagani S, Macha MA, Heimann N, et al. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer[J]. Adv Drug Deliv Rev, 2015, 81: 16-33. [3] Rachagani S,Macha MA,Heimann N,et al. Clinical implications of miRNAs in the pathogenesis,diagnosis and therapy of pancreatic cancer[J]. Adv Drug Deliv Rev,2015,81: 16-33. doi: 10.1016/j.addr.2014.10.020
[4] Listing H, Mardin WA, Wohlfromm S, et al. MiR-23a/-24-induced gene silencing results in mesothelial cell integration of pancreatic cancer[J]. Br J Cancer, 2015, 112(1): 131-9. [4] Listing H,Mardin WA,Wohlfromm S,et al. MiR-23a/-24-induced gene silencing results in mesothelial cell integration of pancreatic cancer[J]. Br J Cancer,2015,112(1): 131-9. doi: 10.1038/bjc.2014.587
[5] Chitkara D, Mittal A, Mahato RI. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies[J]. Adv Drug Deliv Rev, 2015, 81: 34-52. [5] Chitkara D,Mittal A,Mahato RI. miRNAs in pancreatic cancer: therapeutic potential,delivery challenges and strategies[J]. Adv Drug Deliv Rev,2015,81: 34-52. doi: 10.1016/j.addr.2014.09.006
[6] Berindan-Neagoe I,Monroig Pdel C,Pasculli B,et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy[J]. CA Cancer J Clin,2014,64(5): 311-36. doi: 10.3322/caac.21244
[6] Berindan-Neagoe I, Monroig Pdel C, Pasculli B, et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy[J]. CA Cancer J Clin, 2014, 64(5): 311-36. [7] Ali S,Suresh R,Banerjee S,et al. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells[J]. Am J Cancer Res,2015,5(3): 1251-64. http://cn.bing.com/academic/profile?id=2402288178&encoded=0&v=paper_preview&mkt=zh-cn
[7] Ali S, Suresh R, Banerjee S, et al. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells[J]. Am J Cancer Res, 2015, 5(3): 1251-64. [8] Rachagani S,MachA MA,Menning MS,et al. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model[J]. Oncotarget,2015,6(37): 40295-309. http://cn.bing.com/academic/profile?id=2259075239&encoded=0&v=paper_preview&mkt=zh-cn
[8] Rachagani S, MachA MA, Menning MS, et al. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model[J]. Oncotarget, 2015, 6(37): 40295-309. [9] Zou Y, Li J, Chen Z, et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients[J]. Carcinogenesis, 2015, 36(6): 676-84. [9] Zou Y,Li J,Chen Z,et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients[J]. Carcinogenesis,2015,36(6): 676-84. doi: 10.1093/carcin/bgv027
[10] Li BS, Liu H, Yang WL. Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis[J]. Genet Mol Res, 2015, 14(4): 16372-8. [10] Li BS,Liu H,Yang WL. Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis[J]. Genet Mol Res,2015,14(4): 16372-8. doi: 10.4238/2015.December.9.5
[11] Frampton AE, Giovannetti E, Jamieson NB, et al. A microRNA meta-signature for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn, 2014, 14(3): 267-71. [11] Frampton AE,Giovannetti E,Jamieson NB,et al. A microRNA meta-signature for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn,2014,14(3): 267-71. doi: 10.1586/14737159.2014.893192
[12] Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer[J]. JAMA, 2014, 311(4): 392-404. [12] Schultz NA,Dehlendorff C,Jensen BV,et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer[J]. JAMA,2014,311(4): 392-404. doi: 10.1001/jama.2013.284664
[13] Slater EP,Strauch K,Rospleszcz S,et al. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer[J]. Transl Oncol,2014,7(4): 464-71. doi: 10.1016/j.tranon.2014.05.007
[13] Slater EP, Strauch K, Rospleszcz S, et al. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer[J]. Transl Oncol, 2014, 7(4): 464-71. [14] Xu J,Cao Z,Liu W,et al. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study[J]. Ann Surg,2015,263(6): 1173-9. http://cn.bing.com/academic/profile?id=2334205428&encoded=0&v=paper_preview&mkt=zh-cn
[14] Xu J, Cao Z, Liu W, et al. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study[J]. Ann Surg, 2015, 263(6): 1173-9. [15] Chen Q, Yang L, Xiao Y, et al. Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer[J]. Med Oncol, 2014, 31(11): 225. [15] Chen Q,Yang L,Xiao Y,et al. Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer[J]. Med Oncol,2014,31(11): 225. doi: 10.1007/s12032-014-0225-z
[16] Meng QC, Qiu WW, Wen ZQ, et al. Novel blood-based microRNA biomarkers for diagnosis of pancreatic cancer: a metaanalysis[ J]. Tumori, 2015, 101(2): 199-205. [16] Meng QC,Qiu WW,Wen ZQ,et al. Novel blood-based microRNA biomarkers for diagnosis of pancreatic cancer: a meta-analysis[J]. Tumori,2015,101(2): 199-205. doi: 10.5301/tj.5000240
[17] Cote GA,Gore AJ,Mcelyea SD,et al. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile[J]. Am J Gastroenterol,2014,109(12): 1942-52. doi: 10.1038/ajg.2014.331
[17] Cote GA, Gore AJ, Mcelyea SD, et al. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile[J]. Am J Gastroenterol, 2014, 109(12): 1942-52. [18] Xie Z,Yin X,Gong B,et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer[J]. Cancer Prev Res (Phila),2015,8(2): 165-73. doi: 10.1158/1940-6207.CAPR-14-0192
[18] Xie Z, Yin X, Gong B, et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer[J]. Cancer Prev Res (Phila), 2015, 8(2): 165-73. [19] Debernardi S,Massat NJ,Radon TP,et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma[J]. Am J Cancer Res,2015,5(11): 3455-66. http://cn.bing.com/academic/profile?id=2395563932&encoded=0&v=paper_preview&mkt=zh-cn
[19] Debernardi S, Massat NJ, Radon TP, et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma[J]. Am J Cancer Res, 2015, 5(11): 3455-66. [20] Khan S,Ansarullah,Kumar D,et al. Targeting microRNAs in pancreatic cancer: microplayers in the big game[J]. Cancer Res,2013,73(22): 6541-7. doi: 10.1158/0008-5472.CAN-13-1288
[20] Khan S, Ansarullah, Kumar D, et al. Targeting microRNAs in pancreatic cancer: microplayers in the big game[J]. Cancer Res, 2013, 73(22): 6541-7. [21] van der Ree MH,van der Meer AJ,van Nuenen AC,et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma[J]. Aliment Pharmacol Ther,2016,43(1): 102-13. doi: 10.1111/apt.2016.43.issue-1
[21] van der Ree MH, van der Meer AJ, van Nuenen AC, et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma[J]. Aliment Pharmacol Ther, 2016, 43(1): 102-13. [22] Li Y, SarkaR FH. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer[J]. Int J Biol Sci, 2016, 12(3): 326-37. [22] Li Y,SarkaR FH. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer[J]. Int J Biol Sci,2016,12(3): 326-37. doi: 10.7150/ijbs.15017
[23] Passadouro M,Pedroso de Lima MC,Faneca H. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer[J]. Int J Nanomedicine,2014,9: 3203-17. http://cn.bing.com/academic/profile?id=2064911382&encoded=0&v=paper_preview&mkt=zh-cn
[23] Passadouro M, Pedroso de Lima MC, Faneca H. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer[J]. Int J Nanomedicine, 2014, 9: 3203-17. [24] Song W,Li Q,Wang L,et al. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma[J]. Cell Physiol Biochem,2015,35(1): 184-90. doi: 10.1159/000369686
[24] Song W, Li Q, Wang L, et al. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma[J]. Cell Physiol Biochem, 2015, 35(1): 184-90. [25] Pang W, Su J, Wang Y, et al. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancerassociated fibroblasts[J]. Cancer Sci, 2015, 106(10): 1362-9. [25] Pang W,Su J,Wang Y,et al. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts[J]. Cancer Sci,2015,106(10): 1362-9. doi: 10.1111/cas.12747
[26] Kuninty PR,Bojmar L,Tjomsland V,et al. MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor[J]. Oncotarget,2016,7(13): 16396-408. http://cn.bing.com/academic/profile?id=2268705481&encoded=0&v=paper_preview&mkt=zh-cn
[26] Kuninty PR, Bojmar L, Tjomsland V, et al. MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor[J]. Oncotarget, 2016, 7(13): 16396-408. [27] Arora S, Swaminathan S K, Kirtane A, et al. Synthesis, characterization, and evaluation of poly (D,L-lactide-coglycolide)- based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy[J]. Int J Nanomedicine, 2014, 9: 2933-42. [27] Arora S,Swaminathan S K,Kirtane A,et al. Synthesis,characterization,and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy[J]. Int J Nanomedicine,2014,9: 2933-42.
[28] Neault M, Mallette FA, Richard S. miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells[J]. Cell Rep, 2016, 14(8): 1966-78. [28] Neault M,Mallette FA,Richard S. miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells[J]. Cell Rep,2016,14(8): 1966-78. doi: 10.1016/j.celrep.2016.01.068
[29] Wang C, Liu P, Wu H, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3[J]. Oncotarget, 2016, 7(12):14912-24. [29] Wang C,Liu P,Wu H,et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3[J]. Oncotarget,2016,7(12):14912-24. http://cn.bing.com/academic/profile?id=2290307663&encoded=0&v=paper_preview&mkt=zh-cn
[30] Komatsu S,Ichikawa D,Miyamae M,et al. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma[J]. Expert Opin Biol Ther,2015,15(6): 773-85. doi: 10.1517/14712598.2015.1029914
[30] Komatsu S, Ichikawa D, Miyamae M, et al. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma[J]. Expert Opin Biol Ther, 2015, 15(6): 773-85. [31] Frampton AE, Krell J, Jamieson NB, et al. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis[J]. Eur J Cancer, 2015, 51(11): 1389-404. [31] Frampton AE,Krell J,Jamieson NB,et al. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis[J]. Eur J Cancer,2015,51(11): 1389-404. doi: 10.1016/j.ejca.2015.04.006
[32] Khan MA,Zubair H,Srivastava SK,et al. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis,Prognosis,and Therapy[J]. Adv Exp Med Biol,2015,889: 71-87. doi: 10.1007/978-3-319-23730-5
[32] Khan MA, Zubair H, Srivastava SK, et al. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy[J]. Adv Exp Med Biol, 2015, 889: 71-87. [33] Xu J, Wang T, Cao Z, et al. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis[J]. Oncotarget, 2014, 5(16): 6983-93. [33] Xu J,Wang T,Cao Z,et al. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis[J]. Oncotarget,2014,5(16): 6983-93. doi: 10.18632/oncotarget
计量
- 文章访问数: 1670
- HTML全文浏览量: 302
- PDF下载量: 1683
下载:
